DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR MS Speaks
       *****************************************************
   DIR (Abst.) Developing a model of care for home infusions of Tysab...
       4 replies
   DIR Biogen Seeks preliminary injunction in case against Sandoz 
       0 replies
   DIR (AAN) PML risk cut by extending Tysabri dosing interval
       5 replies
   DIR (ACTRIMS) PML incidence rates in US patients treated w/nataliz...
       0 replies
   DIR (Abst.) MS disease activity and disability after discontinuing...
       0 replies
   DIR JCV mutations may predict Tysabri-related PML
       0 replies
   DIR European Commission grants marketing authorization for subcuta...
       1 replies
   DIR (Abst.) PML and the spectrum of JC virus-related disease
       0 replies
   DIR (Abst.) Tysabri better than Gilenya in achieving "no evid...
       0 replies
   DIR (Abst.) Fatal COVID-19 in an MS patient on natalizumab...
       0 replies
       *****************************************************
   DIR Next Page